

CRINETICS PHARMACEUTICALS, INC.

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER

I. Purpose

The general purpose of the Nominating and Corporate Governance Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Crinetics Pharmaceuticals, Inc. (the “*Company*”) is to ensure that the Board is properly constituted to meet its fiduciary obligations to the Company’s shareholders and that the Company has and follows appropriate corporate governance standards. The duties and responsibilities of the Committee are set forth below and include identifying individuals qualified to become Board members consistent with criteria approved by the Board, recommending to the Board for approval all director nominees, including the Company’s slate of director nominees for each annual meeting of shareholders, developing and recommending to the Board for approval a set of Corporate Governance Guidelines and overseeing the annual evaluation of the Board.

II. Composition

The Committee must consist of at least two directors, each of whom must satisfy the applicable independence requirements of the Nasdaq Stock Market LLC (“*Nasdaq*”), subject to any available exception. Committee members shall be appointed by the Board in accordance with the bylaws of the Company. Committee members may be removed, with or without cause, by the Board. Unless a Chair is designated by the Board, the Committee may designate a Chair by majority vote of the full Committee membership.

III. Meetings, Procedures and Authority

The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company’s bylaws that are applicable to the Committee.

The Committee has sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve such search firm’s fees and other retention terms. The Committee has the authority to retain any other advisors that the Committee believes to be desirable and appropriate and has the authority to approve related fees and retention terms. The Committee shall receive appropriate funding from the Company for the payment of compensation to any such adviser retained by the Committee.

In addition to the duties and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities consistent with this Charter, the purposes of the Committee, and the Company’s bylaws.

IV. Duties and Responsibilities

1. *Director Nominees.* The Committee will identify individuals qualified to become members of the Board in accordance with, among other things, the criteria set forth in the Corporate Governance Guidelines and the applicable independence and other requirements of the Nasdaq rules and the rules and regulations of the Securities and Exchange Commission (“*SEC*”), and ensure that the Board has the requisite expertise and that its membership consists of persons with sufficiently diverse and independent backgrounds. The Committee will also recommend to the Board for approval all nominees for election to

the Board, including the Company's slate of nominees for election at each annual meeting of shareholders.

2. *Shareholder Nominees.* The Committee will review any nominees for election to the Board properly nominated by the Company's shareholders in accordance with the Company's bylaws.

3. *Criteria for Selecting Directors and Aligning Board Composition with Corporate Strategy.* The criteria to be used by the Committee in recommending directors and by the Board in nominating directors are as set forth in the Company's Corporate Governance Guidelines. The Committee must ensure that Board composition is aligned with long-term Company strategy by creating a long-term succession plan, enabling regular refreshment of the Board and planning for Board leadership succession.

4. *Board Committee Structure and Membership.* The Committee will periodically review the Board committee structure in accordance with, among other things, the criteria set forth in the Corporate Governance Guidelines and the applicable independence and other requirements of the Nasdaq rules and the rules and regulations of the SEC, and recommend any membership changes to the Board for its approval.

5. *Corporate Governance Guidelines.* The Committee will develop and recommend to the Board for approval the Company's Corporate Governance Guidelines. The Committee will, from time to time as it deems appropriate, review and reassess the adequacy of such Corporate Governance Guidelines and recommend any proposed changes to the Board for approval.

6. *Code of Business Conduct and Ethics.* The Committee will, from time to time as it deems appropriate, review and reassess the adequacy of such Code of Business Conduct and Ethics and recommend any proposed changes to the Board for approval.

7. *Annual Board Evaluations and Fostering Continuous Improvement in Board Performance.* The Committee will oversee the annual self-evaluations of the Board and its committees and enable high-quality continuing education opportunities to prepare the Board to help the Company deliver on its strategic objectives.

8. *Compliance Matters.* The Committee shall be responsible for oversight of all compliance matters of the Company, other than those matters for whom oversight has been specifically provided to another Committee of the Board. The Committee shall periodically receive updates about compliance matters from the General Counsel and/or the Vice President of Corporate Compliance. The Vice President of Corporate Compliance shall have the authority to communicate directly with the Committee about compliance matters, including actual and alleged violations of law and any matters involving criminal or potential criminal conduct.

9. *Size of the Board.* The Committee will periodically review the size of the Board, and may make recommendations to the Board for approval regarding the size of the Board that is most effective in relation to future operations.

10. *Emerging Oversight Topics.* The Committee will periodically review the manner in which the Board and Board committees exercise oversight of emerging matters including artificial intelligence, climate risk/sustainability and ESG. The Committee shall be specifically responsible for oversight of matters related to corporate governance, environmental, climate, and other sustainability matters; the Company's current and planned engagement with and use of AI and the Company's related reporting to shareholders, in coordination with other committees or the Board as necessary or appropriate.

11. *Other Corporate Governance Matters.* The Committee may make recommendations to

the Board regarding governance matters, including, but not limited to, proposed amendments to the Company's certificate of incorporation, bylaws, and the charters of the Company's other committees.

12. *Reports to the Board.* The Committee must report regularly to the Board regarding the activities of the Committee.

13. *Committee Self-Evaluation.* The Committee must annually perform an evaluation of the performance of the Committee.

14. *Review of this Charter.* The Committee must annually review and reassess this Charter and submit any recommended changes to the Board for its consideration.

V. Delegation of Duties

In fulfilling its responsibilities, the Committee has the authority to delegate any or all of its responsibilities to a subcommittee of the Committee.

EXHIBIT F

GLOBAL THERAPEUTIC STRATEGY AND ACCESS COMMITTEE CHARTER

CRINETICS PHARMACEUTICALS, INC.

GLOBAL THERAPEUTIC STRATEGY AND ACCESS COMMITTEE CHARTER

I. Purpose

The purpose of the Global Therapeutic Strategy and Access Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Crinetics Pharmaceuticals, Inc. (the “*Company*”) shall be to advise and assist the Board with the following matters:

- a) Oversight, evaluation and guidance regarding the Company’s overall investment in and strategic direction with respect to the Company’s product commercialization efforts.
- b) Provide strategic and operational advice to the Company’s prioritization decisions regarding the allocation, deployment, utilization of and investment in the Company’s products and advancement of therapeutics strategy and operations.
- c) To be available as a resource for management of the Company to consult with regarding Commercial matters as reasonably requested.

II. Membership

The Committee shall be composed of not less than three non-employee directors, all of whom shall meet the Nasdaq Stock Market LLC (“*Nasdaq*”) requirements for director independence. The Committee members shall be appointed by the Board in accordance with the bylaws of the Company and shall serve at the discretion of the Board. Committee members may be removed, with or without cause, by the Board. Unless a Chair is designated by the Board, the Committee may designate a Chair by majority vote of the full Committee membership.

III. Meetings, Procedures and Authority

The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company’s bylaws that are applicable to the Committee.

The Committee has the sole authority to retain or obtain advice from its own scientific, medical and risk management advisors as the Committee believes to be desirable and appropriate and has the authority to approve related fees and retention terms. The Committee shall receive appropriate funding from the Company for the payment of compensation to any such adviser retained by the Committee.

The Committee will meet from time to time, coincident with regularly scheduled Board meetings and more frequently as circumstances require.

IV. Corporate Staff

The Chief Commercial Officer of the Company shall support the Committee and shall attend Committee meetings if and when directed by the Committee Chair. The Committee and its members may talk directly

and privately with any members of Management in discharging Committee responsibilities. The Committee or its Chair may request that any officer or employee of the Company attend any Committee meeting.

V. Duties and Responsibilities

In the discharge of its responsibilities the Committee will:

1. Review, evaluate, and advise the Board and the Company regarding the Company's commercialization strategy;
2. Assist the Board and Management in evaluating and overseeing the Company's short-term key results and long-term strategic objectives related to the Company's product commercialization or business development plans;
3. Assess the capabilities of key personnel and the appropriateness of commercialization resources available to the Company;
4. Provide guidance to Management and the Board on the competitive landscape, pricing strategies and assumptions, commercial market assumptions, commercial developments, potential future innovations, valuation and long-range planning for commercialization or business development, as appropriate; and
5. Review and reassess the adequacy of this Charter from time to time, but no less than annually, and recommend any proposed changes to the Board for consideration.
6. Undertake such additional activities within the scope of its primary functions as the Committee may from time to time determine.

VI. Delegation of Duties

In fulfilling its responsibilities, the Committee has the authority to delegate any or all of its responsibilities to a subcommittee of the Committee.